NAMI-A 是一种基于钌的抗转移剂和抗癌剂,可降低 α5β1 整合素的表达水平、减少 FAK 的 Tyr397 自磷酸化、抑制 MMP-2 和 MMP-9 的酶活性、阻断 KCa3.1 电流,并结合纤维状胶原蛋白和 IV 型胶原蛋白,同时诱导细胞凋亡 (Apoptosis) 以及 G2/M 期和 S 期细胞周期阻滞,抑制血管生成,发挥免疫调节剂的作用,具有选择性抗转移活性,可用于结直肠癌、白血病以及实体瘤肺转移的相关研究。
产品编号: MS-Z88954 纯度: 98.0% CAS No.: 201653-76-1 分子式: C5H10Cl4N2ORuS.C3H4N2.H 分子量: 458.18
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in Water
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

NAMI-A 是一种基于钌的抗转移剂和抗癌剂,可降低 α5β1 整合素的表达水平、减少 FAK 的 Tyr397 自磷酸化、抑制 MMP-2 和 MMP-9 的酶活性、阻断 KCa3.1 电流,并结合纤维状胶原蛋白和 IV 型胶原蛋白,同时诱导细胞凋亡 (Apoptosis) 以及 G2/M 期和 S 期细胞周期阻滞,抑制血管生成,发挥免疫调节剂的作用,具有选择性抗转移活性,可用于结直肠癌、白血病以及实体瘤肺转移的相关研究。

生物实验数据

生物活性 NAMI-A is a ruthenium-based antimetastatic and anticancer agent that decreases the expression level of α5β1 integrin, reduces Tyr397 autophosphorylation of FAK, inhibits the enzymatic activity of MMP-2 and MMP-9, blocks KCa3.1 currents, and binds to fibrillar collagen and type IV collagen, while inducing apoptosis and G2/M and S phase cell cycle arrest, inhibiting angiogenesis, acting as an immunomodulator, exhibiting selective antimetastatic activity, and being applicable to research related to colorectal cancer, leukemia, and solid tumor lung metastasis.
IC50 & Target

αvβ1

 

MMP-9

 

MMP-2

 

Collagen IV

 

体外研究
(In Vitro)

NAMI-A (1-100 μM; 1 h) 可在 1 μM 和 100 μM 浓度下强效抑制 HCT-116 结直肠腺癌细胞通过 Matrigel 的趋化性侵袭,与未处理细胞相比,侵袭能力降低约 30%。
NAMI-A (1-100 μM; 1 h) 以逆浓度依赖方式降低 HCT-116 结直肠腺癌细胞对纤连蛋白、I 型胶原蛋白和层粘连蛋白-111 的黏附性,在 1 μM 时抑制作用达到最大,且其作用通过 α5β1 整合素通路介导。
NAMI-A (3-300 μM; 72 h) 在孵育 72 h 后,浓度高达 100 μM 时对 HCT-116 结直肠腺癌细胞无细胞毒性,仅在浓度 ≥300 μM 时才会观察到细胞活力下降。
NAMI-A (1-100 μM; 1 h) 可抑制 HCT-116 结直肠腺癌细胞中 FAK 在 Tyr397 位点的自磷酸化,其中 1 μM 时抑制作用最强,10 μM 时抑制作用中等。
NAMI-A (1-100 μM; 1-72 h) 在浓度高达 100 μM、处理时长长达 72 h 时,对 TS/A 腺癌细胞的增殖或活力无显著影响。
NAMI-A (0-6 mM; 30 min at 4°C followed by 18 h at 37°C) 可浓度依赖性地抑制 SK-N-BE 神经母细胞瘤和 HT-1080 纤维肉瘤细胞条件培养基中 MMP-2 和 MMP-9 的活性。
NAMI-A (1-20 μM; 24-72 h) 可强效抑制 HL60、FLG 29.1、K562、697 和 REH 白血病细胞系的增殖并诱导其凋亡,其 LD50 值范围为 0.47 μM 至 5.47 μM,但对 IGROV-1 卵巢癌细胞的细胞毒性极低,其 LD50 为 429.87 μM。
NAMI-A (0-100 μM) 可抑制 FLG 29.1 白血病细胞中的 K+ 电流,并选择性阻断 HEK 293-KCa3.1 细胞中的 KCa3.1 通道;在 1-2 μM 浓度下抑制率约为 30%,且在 0.2 μM 至 100 μM 范围内呈现浓度依赖性抑制作用。
NAMI-A (20-80 μM; 24 h) 可剂量依赖性地抑制 HUVEC 和 EA.hy926 细胞的趋化作用,在预处理 24 h 后,40 μM 浓度下可使细胞迁移能力降低 50%,且不会诱导细胞毒性或增殖抑制。
NAMI-A (0.1 mM; 1 h) 可显著改变 KB 上皮癌细胞的细胞周期分布,使其向 S 期和 G2-M 期偏移;且同时给予或后续给予抗坏血酸、谷胱甘肽或半胱氨酸均不会改变该效应。

Cell Invasion Assay

Cell Line: HCT-116 colorectal adenocarcinoma cells
Concentration: 1 μM, 10 μM, 100 μM (1 h pre-treatment)
Incubation Time: 96 h (invasion incubation)
Result: Reduced HCT-116 cell invasion through Matrigel by approximately 30% at 1 μM and 100 μM compared to untreated controls (p < 0.01).
Showed no significant effect on invasion at 10 μM.
Exerted anti-invasive activity only for chemotactic invasion towards FBS; no effect was detected on spontaneous cell invasion.

Western Blot Analysis

Cell Line: HCT-116 colorectal adenocarcinoma cells
Concentration: 1 μM, 10 μM, 100 μM (1 h pre-treatment)
Incubation Time: 1 h (adhesion incubation)
Result: Reduced P-Y397-FAK levels by approximately 70% at 1 μM (p < 0.01) and approximately 15% at 10 μM (p < 0.05) relative to untreated controls.
Showed no significant reduction in P-Y397-FAK levels at 100 μM.

Cell Migration Assay

Cell Line: human umbilical vein endothelial cells (HUVEC), human endothelial-like immortalised EA.hy926 cells
Concentration: 20 μM, 40 μM, 80 μM
Incubation Time: 24 h (pre-treatment); 6 h (chemotaxis incubation)
Result: Caused a progressive dose-dependent inhibition of HUVEC and EA.hy926 cell migration towards the NIH3T3 chemoattractant.
Reduced migration by 50% at 40 μM compared to positive controls.
Showed no inhibition of cell proliferation or cytotoxicity after 24 h of treatment at these concentrations.
体内研究
(In Vivo)

NAMI-A (腹腔注射;单剂量或重复,35-193 mg/kg) 可显著降低 MCa 乳腺癌小鼠的肺转移形成率,且在所有测试剂量和处理方案下均有效;仅在单次给予 137 mg/kg 剂量时,可观察到原发肿瘤生长受到抑制。
NAMI-A (35 mg/kg/天;腹腔注射;共 5 次) 可降低 BD2F1 小鼠体内 Lewis 肺癌细胞的转移潜能,在全部四代移植过程中对肺转移灶的数量和重量均具有统计学意义的抑制作用,但对原发肿瘤生长无影响。
NAMI-A (120-240 μM;明胶海绵局部给予) 在 FGF-2 诱导的鸡胚绒毛尿囊膜 (CAM) 模型中表现出剂量依赖性的体内抗血管生成活性,与单独使用 FGF-2 相比,120 μM 剂量下可使宏观血管计数减少约 71%、微血管密度减少约 68%,240 μM 剂量下可使宏观血管计数减少约 87%、微血管密度减少约 88%。
NAMI-A (35 mg/kg/天;腹腔注射;每日给予;共 6 天) 在注射前放置时长达到 8 h 时仍保持完整的抗转移活性 (肺转移重量 %T/C ≤19),放置 24 h 后仅观察到活性下降 25%,同时对原发肿瘤生长无影响或仅产生轻微影响。
NAMI-A (15-50 mg/kg/天;静脉注射;每日;连续 5 天) 在瑞士 CD1 小鼠中耐受性良好,仅产生可逆的轻微作用;而 50 mg/kg/天的剂量会引发剂量限制性毒性,且雌性小鼠致死率更高;所有剂量均表现出快速血液清除特性,无法穿透血脑屏障,且会优先滞留于肝脏、肾脏和肺部。
NAMI-A (35 mg/kg/天;腹腔注射;每日;连续 6 天) 可显著延长多种小鼠实体瘤模型的生存期并减少肺转移,且不影响原发肿瘤生长。

Animal Model: CBA mice (female)
Dosage: 35-193 mg/kg
Administration: i.p.; single dose; repeated doses (once every 72 hours for 4 doses; once every 48 hours for 5 doses; daily for 6 doses)
Result: Reduced primary tumor growth only at the 137 mg/kg single dose.
Significantly reduced the number and weight of lung metastases across all tested doses and schedules, with no statistically significant differences in antimetastatic efficacy between different doses or schedules.
Animal Model: BD2F1 mice (female)
Dosage: 35 mg/kg/day
Administration: i.p.; daily; 5 doses (days 10-14)
Result: Reduced lung metastasis number and weight by statistically significant amounts in the initial generation (generation 0) relative to controls.
Maintained statistically significant reduction of lung metastasis number and weight through all three subsequent transplant generations (generations 1, 2, 3) in untreated mice.
Showed reduced but still significant inhibition of lung metastasis weight in generation 2.
Caused no statistically significant difference in primary tumor weight relative to controls across any generation.
Animal Model: CBA mice (female, inbred strain, implanted intramuscularly with 1×106 MCa mammary carcinoma cells)
Dosage: 35 mg/kg/day
Administration: i.p.; daily; 6 days
Result: Showed no significant reduction in primary tumour weight across all ageing conditions (0 h: 2152 mg; 4 h: 1954 mg; 8 h: 2072 mg; 24 h: 2184 mg, with or without 5% DMSO) compared to controls.
Reduced lung metastasis number to 12.1 (%T/C = 40, P<0.05 vs. control) and metastasis weight to 26 mg (%T/C = 16, P<0.01 vs. control) when used as fresh solution (0 h) without DMSO.
Reduced lung metastasis number to 15.1 (%T/C = 57, P<0.05 vs. control) and metastasis weight to 29 mg (%T/C = 19, P<0.01 vs. control) when used as fresh solution (0 h) with 5% DMSO.
Reduced lung metastasis number to 12.2 (%T/C = 41, P<0.05 vs. control) and metastasis weight to 23 mg (%T/C = 14, P<0.01 vs. control) when used as 4 h aged solution without DMSO.
Reduced lung metastasis number to 13.4 (%T/C = 51, P<0.05 vs. control) and metastasis weight to 29 mg (%T/C = 19, P<0.01 vs. control) when used as 4 h aged solution with 5% DMSO.
Reduced lung metastasis weight to 32 mg (%T/C = 19, P<0.01 vs. control) when used as 8 h aged solution without DMSO; showed no significant reduction in lung metastasis number (%T/C = 56).
Reduced lung metastasis weight to 34 mg (%T/C = 22, P<0.01 vs. control) when used as 8 h aged solution with 5% DMSO; showed no significant reduction in lung metastasis number (%T/C = 66).
Reduced lung metastasis weight to 50 mg (%T/C = 31, P<0.01 vs. control) when used as 24 h aged solution without DMSO; showed no significant reduction in lung metastasis number (%T/C = 74).
Reduced lung metastasis number to 23.5 (%T/C = 86, P<0.05 vs. control) and metastasis weight to 57 mg (%T/C = 37, P<0.05 vs. control) when used as 24 h aged solution with 5% DMSO.\nReduced lung metastasis number to 7.0 (%T/C = 42) and metastasis weight to 15.2 mg (%T/C = 16, P<0.05 vs. control) when administered alone in Experiment 1.
Reduced lung metastasis number to 27.5 (%T/C = 62) and metastasis weight to 83.6 mg (%T/C = 45, P<0.05 vs. control) when administered alone in Experiment 2.
Achieved 5 out of 6 mice free of macroscopic lung metastases, with average metastasis number of 4.0 and metastasis weight of 15.2 mg (%T/C = 16) when reduced with ascorbic acid in Experiment 1.
Reduced lung metastasis number to 3.5 (%T/C = 14) and metastasis weight to 9.2 mg (%T/C = 10, P<0.05 vs. control) when reduced with cysteine in Experiment 1.
Reduced lung metastasis number to 23.1 (%T/C = 52) and metastasis weight to 47.1 mg (%T/C = 26, P<0.05 vs. control) when reduced with glutathione in Experiment 2.
Reduced lung metastasis number to 19.2 (%T/C = 43) and metastasis weight to 44.2 mg (%T/C = 24, P<0.05 vs. control) when reduced with cysteine in Experiment 2.
Resulted in higher ruthenium concentration in lungs compared to reduced NAMI-A formulations when administered alone.
Reduced damaged kidney glomeruli to 8.50% (P<0.05 vs. 12.03% with NAMI-A alone) when combined with glutathione.
Animal Model: Not specified (tumor-bearing)
Dosage: 35 mg/kg/day
Administration: i.p.; daily; 6 consecutive days
Result: Significantly prolonged life expectancy in treated animals.
Strongly reduced lung metastases.
Showed no significant effect on primary tumor mass.
性状 固体
颜色 Pink to red

化学信息

分子量 458.18
分子式 C5H10Cl4N2ORuS.C3H4N2.H
CAS No. 201653-76-1

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 8.28 mg/mL (18.07 mM; 超声加热助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM2.1825 mL10.9127 mL21.8255 mL54.5637 mL
5 mM0.4365 mL2.1825 mL4.3651 mL10.9127 mL
10 mM0.2183 mL1.0913 mL2.1825 mL5.4564 mL
15 mM0.1455 mL0.7275 mL1.4550 mL3.6376 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础